| Literature DB >> 25821434 |
Icksoo Lee1, Maik Hüttemann2, Adele Kruger3, Aliccia Bollig-Fischer4, Moh H Malek5.
Abstract
The purpose of this study was to conduct an 8 week endurance training program with and without (-)-epicatechin treatment and to determine whether there is a possible cumulative effect on protein markers of angiogenesis and mitochondrial biogenesis. Thirty-four 14-month old male mice (C57BL/6N) were randomized into four groups: control (C); (-)-epicatechin only ((-)-Epi); control with endurance training (CE); and (-)-epicatechin with endurance training ((-)-Epi-Ex). Mice in the training groups performed treadmill exercise for 8 weeks (5 × /week for 60 min/session), whereas mice in the (-)-epicatechin group received 1.0 mg/kg of body mass twice daily during the training period. At 8 weeks, distance ran on the treadmill increased by 46, 69, and 84% in the (-)-Epi, CE, and (-)-Epi-Ex groups, respectively compared to the control group (p < 0.001 for all comparisons). Furthermore, the (-)-Epi-Ex group had significantly higher exercise capacity than the (-)-Epi and CE group. For angiogenic regulators, the (-)-Epi-Ex group had significantly higher VEGF-R2 protein expression with a concomitant reduction in TSP-1 protein expression than the exercise group. Interestingly, FoxO1 protein expression was significantly reduced for all three experimental groups compared to the control group. Protein markers such as PGC-1β and TFAM were significantly higher in the (-)-Epi-Ex group compared to the three other groups. These findings suggest that (-)-epicatechin treatment combined with 8 weeks of endurance training provide a cumulative effect on a number of angiogenic and mitochondrial signaling which functionally translates to enhanced exercise tolerance.Entities:
Keywords: exercise tolerance; fatigue; mitochondrial proteins; mouse model; muscle; skeletal
Year: 2015 PMID: 25821434 PMCID: PMC4358069 DOI: 10.3389/fphar.2015.00043
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Comparisons of body and muscle masses across the four groups (mean ± SEM).
| 0-weeks | 4-weeks | 8-weeks | 0-weeks | 4-weeks | 8-weeks | 0-weeks | 4-weeks | 8-weeks | 0-weeks | 4-weeks | 8-weeks | |
| Body mass (g) | 33.8 ± 0.9 | 32.6 ± 0.8 | 34.0 ± 0.9 | 31.4 ± 0.8 | 30.8 ± 0.8 | 31.7 ± 0.8 | 33.7 ± 0.8 | 32.3 ± 0.8 | 32.1 ± 0.8 | 33.2 ± 0.9 | 32.0 ± 0.8 | 31.7 ± 0.9 |
| Plantaris mass ( mg) | – | – | 17.3 ± 0.7 | – | – | 11.7 ± 0.3* | – | – | 16.9 ± 0.3 | – | – | 11.4 ± 0.3* |
| Plantaris/body mass (mg·g–1) | – | – | 0.51 ± 0.02 | – | – | 0.37 ± 0.02* | – | – | 0.53 ± 0.02 | – | – | 0.36 ± 0.01* |
| Lateral gastrocnemius mass (mg) | – | – | 87.0 ± 2.8 | – | – | 89.1 ± 1.1 | – | – | 69.6 ± 2.1** | – | – | 67.5 ± 2.9** |
| Lateral gastrocnemius/body mass (mg·g–1) | – | – | 2.6 ± 0.1 | – | – | 2.8 ± 0.1 | – | – | 2.2 ± 0.1t | – | – | 2.1 ± 0.1***,† |
| Quadriceps femoris mass (mg) | – | – | 213.3 ± 2.1 | – | – | 191.4 ± 6.1* | – | – | 212.0 ± 4.5 | – | – | 205.3 ± 4.1 |
| Quadriceps femoris/body mass (mg·g–1) | – | – | 6.3 ± 0.2 | – | – | 6.1 ± 0.2 | – | – | 6.6 ± 0.2 | – | – | 6.5 ± 0.1 |
*Significantly (p < 0.001) different from control and CE groups, **significantly (p < 0.001) different from control and (–)–Epi groups, ***significantly (p < 0.05) different from control group, †significantly (p ≤ 0.003) different from (–)–Epi group.
FIGURE 1Measurements of capillarity for the plantaris muscle. (A) (N): *significantly different than control group (p < 0.0001); †significantly different than Epi and CE groups (p < 0.0001). (B) (CD): *significantly different than control group (p ≤ 0.018); †significantly different than Epi (p = 0.043) and CE (p = 0.005) groups. (C) (C/F): *significantly different than control group (p < 0.001); †significantly different than Epi and CE groups (p = 0.001). (D) (CFPE): *significantly different than control group (p ≤ 0.013); †significantly different than Epi (p = 0.037) and CE (p = 0.006) groups. (n = 3 per group; mean ± SEM).
Morphometric analyses of the plantaris muscle (mean ± SEM).
| Plantaris muscle | ||||
| Area (μm) | 2645 ± 125 | 2375 ± 98 | 2667 ± 219 | 2337 ± 98 |
| Perimeter (μm) | 215 ± 14 | 203 ± 5 | 221 ± 9 | 204 ± 7 |
No significant differences between groups for either index.
FIGURE 2Basal pro- and anti-angiogenic responses in the quadriceps femoris muscle following 8 weeks of endurance training with and without (–)–epicatechin. (A) are representative Western blots. (B) (VEGF-A) there was no significant difference between groups. (C) (VEGF-R2): *significantly (p < 0.03) different than control; **significantly (p = 0.018) different than CE; and †significantly (p = 0.002) different than CE. (D) (ADAMTS-1): *significantly (p ≤ 0.03) different than control. (E) (TSP-1): *significantly (p < 0.001) different than control; ††significantly (p < 0.04) different than (–)–Epi and CE groups. (F) (CD47) there was no different between groups for TSP-1 receptor. (G) (FOXO1): *significantly (p < 0.04) different than control. (n = 4–5 animals per group; mean ± SEM).
FIGURE 3Basal protein expression of mitochondrial biogenesis regulators in the quadriceps femoris muscle following 8 weeks of endurance training with and without (–)–epicatechin. (A) are representative Western blots. (B) (PGC-1α and PGC-1β): no significant differences between groups for PGC-1α, whereas for PGC-1β *significantly (p ≤ 0.014) different than control group; ††significantly (p ≤ 0.02) different than (–)–Epi and CE groups. (C) (TFAM): *significantly (p < 0.04) different than control group; and ††significantly (p ≤ 0.015) different than (–)–Epi and CE groups. (n = 4–5 animals per group; mean ± SEM).
FIGURE 4Citrate synthase and cytochrome c oxidase activity is increased in the hindlimb muscles after (–)–epicatechin treatment. (A) is citrate synthase activity in the lateral gastrocnemius muscle normalized to the control group *significantly different than control [p-values ranged from ≤ 0.007 to 0.048; ††different than (–)–Epi and CE, p < 0.0001; n = 4 animals per group]. (B) is CcO activity which was determined in the muscle of mice in the control group incubated in the presence (20 μM final concentration; triangle) or absence (vehicle, circle) of (–)–epicatechin for 25 min using the polarographic method by increasing the amount of substrate cytochrome c. CcO activity is defined as consumed [O2 (μM)/min/protein mg] (*p ≤ 0.001 significantly different from placebo group, n = 4–5 animals per group, mean ± SEM).